Lithuania asks NATO for more air defences after drones land on its territory
"This must not be only Lithuania's responsibility, because we are defending the eastern NATO flank," Foreign Minister Kestutis Budrys told reporters.
NATO and European Union member Lithuania borders Russia and Moscow's ally, Belarus.
The letter from Lithuania's foreign and defence ministers to NATO General Secretary Mark Rutte said the alliance must show it is ready to defend "every centimetre of its territory".
In the most recent incident, a drone crossed into Lithuania on July 28, which Lithuania suspects was directed by Russia at Ukraine, but that it was disoriented by Ukraine's defences, Defence Minister Dovile Sakaliene said on Tuesday.
The drone was found crashed in a military training area about 100 kilometres (62.14 miles) from the border with Belarus and contained 2 kg (4 lb) of explosives, the chief of staff of the Lithuanian army, Dainius Paskevicius, told reporters.
Sakaliene had earlier identified the object as a Gerbera drone, a wooden copy of an Iranian-designed Shahed kamikaze drone, which Russian military is known to use.
Another Gerbera drone entered Lithuania from Belarus on July 10, causing alarm before authorities determined it was not dangerous.
Then-prime minister Gintautas Paluckas and Speaker of Parliament Saulius Skvernelis were briefly taken to bomb shelters in response to the drone entering Lithuanian airspace, according to their spokespersons.
NATO was not immediately available for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
27 minutes ago
- The Independent
‘Tattletale' Kemi Badenoch got a fellow pupil expelled after catching him cheating in exam
Kemi Badenoch has said that she was a 'tattle-tale' in school, revealing that she got a fellow pupil expelled after she caught him cheating in an exam. During an interview with Amol Rajan in his Interviews... series released on Thursday (7 August), the Conservative leader said that when she was '14 or 15' she stood up in the middle of a test and called out a boy who was breaking the rules. 'I've always hated cheating. I've done all the work and then there's some people who are copying notes and why should they get away with it?,' she said. She shared that she received no praise for 'snitching' on her fellow pupil, with one student telling her: 'You don't belong here.' Rajan quipped 'no wonder you were so unpopular back in school'.
Reuters
28 minutes ago
- Reuters
Focus: Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say
NEW YORK, Aug 7 (Reuters) - The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt "most favored nation" pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being "ripped off." The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America - the industry's main lobby group - has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. "Prices can come down in the United States without being increased in other countries, and we can still get innovation," she said. Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. "This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it," the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. "There's a big push from the administration to drive up prices outside the U.S.," the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca (AZN.L), opens new tab, Bayer ( opens new tab and Novo Nordisk ( opens new tab signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. "It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction," Kaltenboeck said, "and it doesn't make much sense for them politically."
Reuters
an hour ago
- Reuters
European shares tick higher with earnings, tariffs in focus
Aug 7 (Reuters) - European shares ticked higher on Thursday, as investors weighed mixed earnings reports and the impact from higher U.S. tariffs on a dozen of its trading partners that are expected to weigh on global growth and rekindle inflation. The pan-European STOXX 600 index (.STOXX), opens new tab rose 0.6%, as of 0855 GMT, with most major regional bourses trading higher. Britain's blue-chip FTSE 100 (.FTSE), opens new tab, however, dipped 0.3% ahead of a Bank of England meeting where policymakers are widely expected to cut interest rates. U.S. President Donald Trump's higher tariffs kicked in on Thursday, including a 39% rate on Switzerland. Swiss President Karin Keller-Sutter left Washington on Wednesday after failing to meet with Trump or any top trade officials, a source told Reuters. Trump also said the United States will impose a tariff of about 100% on imports of semiconductors but offered up a big exemption - it will not apply to companies that are manufacturing in the U.S. or have committed to do so. European tech stocks (.SX8P), opens new tab, particularly those of chipmakers, climbed on relief that there will be no charge on companies such as Apple that has committed to build in the United States. European chipmakers BE Semiconductor ( opens new tab, ASML Holding ( opens new tab and SAP ( opens new tab were all up over 2%. Broad hopes that tech companies will be spared from Trump's big tariffs helped offset weak economic data and some earnings disappointments. German industrial output fell in June to its lowest level since the pandemic, with exports rising more than expected amid weak foreign demand and increased competition from China. In earnings, Rheinmetall ( opens new tab was among top laggards on the index, falling 5.2%, after the German defence company missed second-quarter sales expectations partially due to a delay in German defence contracts being awarded. On the flip side, Maersk ( opens new tab rose 2.5% after the shipping group raised its full-year profit outlook on global demand for ocean container freight. "I think it's safe to say the impact on profits in this quarter has been negative but not as bad as expected," said Daniel Morris, chief market strategist at BNP Paribas Asset Management. "One of the reasons is you'd already priced in that impact on profits and it's turned out to be a little bit better than you thought." Of the 198 companies in the STOXX 600 that reported earnings through Tuesday, 53% exceeded analysts' estimates, as per data compiled by LSEG. In a typical quarter, 54% beat forecasts. Telecommunication stocks (.SXKP), opens new tab were under pressure after Freenet AG ( opens new tab and DT Telekom ( opens new tab fell 5.3% and 3.6%, respectively, after their quarterly results. Austria's Raiffeisen Bank International ( opens new tab jumped to the top of STOXX 600, adding 10.3% after a Russian court lifted a temporary freeze of the bank's Russian unit shares. InterContinental Hotels Group (IHG.L), opens new tab rose 6% after posting a strong half-year revenue and maintaining full-year targets. Merck KGaA ( opens new tab fell 1.4% after the German drugmaker narrowed its guidance range for organic sales and posting a lower second-quarter adjusted EBITDA due to a weaker dollar.
